health
Medetomidine Reached About a Quarter of Fentanyl Samples in a Southern California Drug-Checking Study
A medRxiv preprint reports that medetomidine’s co-presence in fentanyl samples submitted to a Southern California drug-checking programme rose from about 6% in May 2025 to about 25% by August 2026. The study analysed drug samples, not patient outcomes, and has not yet undergone peer review.